Fragile X syndrome clinical trials: exploring parental decision-making.
C S D'Amanda, H L Peay, A C Wheeler and 2 others
PMID 30747463WHAT IT FOUND
Parents choosing fragile X drug trials weighed hoped-for benefit, medication attitudes, symptom match, side effects, and burden.
Ease varied, but all said they chose rightly at the time. The study describes decisions, not whether trials help.
Key findings
01Parents who joined trials all believed participation offered direct benefit, and some also wanted to benefit the fragile X community.
02Parents who declined most often cited a poor match between the trial's target outcome and their child's symptoms, plus travel, scheduling, or appointment burden.
03Parents described ranging ease of decision-making, but all reported feeling they made the right choice given what they knew at the time.
STILL TO COME
How it was doneWhat they found
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
Parents were recruited through fragile X support organizations, so they may have had more resources or stronger views about research than families not connected to those groups. Participants volunteered, so parents most comfortable or most conflicted about their decision may be over-represented. Many decisions happened years earlier, and 9 decliners did not recall the specific trials, so reasons may be reconstructed. Most participants were female (84%), married (81%), and white (84%), and only English-speaking parents were eligible, so the sample may not reflect broader fragile X families. This is a qualitative study of reasons and feelings. It does not show whether any drug trial helped or harmed children.
Declared interests
The authors declare that there is no conflict of interest.
The easy way to misread this
Do not read this as evidence that fragile X drug trials are effective or that parents should enroll. It reports parents' reasons and feelings, not child outcomes, and the sample came from support organizations with recall limitations.